NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Dr. Michael E. KAMARCK
Dr. Michael D. KOWOLENKO
Joseph M. MAHADY
Douglas A. ROGERS
Wyeth Hires and Promotes Executives
Wyeth, Madison, N.J., has announced a number of executive hires and promotions at its pharmaceuticals and consumer health divisions. At Wyeth Pharmaceu ticals, Collegeville, Pa., Michael E. Kamarck, Ph.D., has been promoted to executive VP, technical operations and product supply, from his previous role as senior VP, technical operations and product supply. In this new role, Dr. Kamarck is respon sible for leading the effort to integrate Wyeth Pharmaceuticals’ biotech and pharmaceutical operating units and align them with the divi sion’s commercial and R&D organizations. Wyeth Pharmaceuti cals has appointed Michael D. Kowolenko, Ph.D., to succeed Dr. Kamarck as senior VP, technical operations and product supply for the division’s biotech operat ing unit. Dr. Kowolenko was most recently senior VP, pharmaceutical operations and technology, at Biogen Idec. Joseph M. Mahady has been promoted to presi dent of Wyeth Pharma ceuticals, as well as a senior VP of Wyeth. Mr. Mahady was previously president, global busi ness, with responsibility for all of Wyeth Pharma ceuticals’ commercial businesses worldwide. He received a pharmacy degree from St. John’s University College of Pharmacy and an MBA from Fairleigh Dickinson University. Wyeth Consumer Healthcare, Madison, N.J., has promoted Cavan M. Redmond to president, with responsibility for the division’s global opera tions. Mr. Redmond pre viously served as executive VP and general manager of the BioPharma business unit of Wyeth Phar maceuticals. He received a bachelor’s degree in political science from the University of Mary land and a master’s degree in administration from The Johns Hopkins University. Douglas A. Rogers has been appointed to the newly created position of president, U.S., and glob al new business, for Wyeth Consumer Healthcare. Mr. Rogers most recently was presi dent of Wyeth Consumer Healthcare. He received a bachelor’s degree in journalism and an MBA, both from Lehigh University. Dr. John C. LECHLEITER Lilly Names CEO Successor Eli Lilly, Indianapolis, has named president and chief operating officer John C. Lechleiter, Ph.D., to succeed retiring CEO Sidney Taurel, effective April 1. Mr. Taurel will continue as Lilly’s chairman until the end of the year. Dr. Lechleiter has been with Lilly for 28 years, and has served as president and chief operating officer of Lilly since October 2005. He continues his role as president of Lilly. He received a B.S. summa cum laude in chemistry from Xavier University and studied organic chemistry as a National Science Foundation Fellow at Harvard University, where he was granted his mas ter’s and doctorate degrees. Kenneth L. MURTHA AstraZeneca Expands Operations VP Post AstraZeneca, Wilm ington, Del., has appoint ed Kenneth L. Murtha to the newly expanded role of regional supply VP, the Americas. Mr. Murtha was previously VP, busi ness operations, for the United States. In addition to his North American responsibilities, Mr. Murtha now oversees distribution in Latin America and supply sites in Argentina, Brazil, Puerto Rico, and Mexico. Mr. Murtha received a bachelor’s degree in pharmacy from the University of Pittsburgh. Biotech POOL Dr. Raymond T. BARTUS Ceregene Announces R&D Promotion Ceregene, a San Diegobased biotechnolo gy company focused on the development of gene therapies for neurodegen erative disorders, has pro moted Raymond T. Bar tus, Ph.D., to executive VP of clinical and preclin ical R&D and chief operating officer. Previ ously, he was senior VP of clinical and preclin ical R&D and chief operating officer. Dr. Bartus has 30 years of experience in the biotech and pharmaceutical industry. TALENT POOL EXECUTIVE APPOINTMENTS AND PROMOTIONS IN THE HEALTHCARE INDUSTRY 0208issue FINAL 1/18/08 5:36 PM Page 64 65 PharmaVOICE F e b r u a r y 2 008 TALENT pool Dr. Mark FROHLICH Dendreon Names Medical Chief Dendreon, a Seattlebased biotechnology company focused on oncology therapeutics, has promoted Mark Frohlich, M.D., to senior VP of clinical affairs and chief medical officer. Dr. Frohlich was previously VP of clinical affairs. He received a B.S. in electrical engineering and economics from Yale University and an M.D. from Harvard Medical School. Dr. Franois MARTELET Avax Appoints New CEO Avax Technologies, Philadelphia, has named Dr. Franois Martelet president and CEO, replacing Richard Rainey, who is con tinuing as chief financial officer until at least May 31. Dr. Martelet was most recently VP and global franchise head, oncology, at Merck. He received a master’s degree in business and a doctorate in medicine with distinction, both from Dijon University in France, as well as a degree in legal medicine from R. Descartes University School of Medicine in Paris. Biopharmaceutical POOL Michael D. BECKER VioQuest Appoints CEO VioQuest Pharmaceu ticals, a Basking Ridge, N.J.based biopharma ceutical company focused on developing cancer therapeutics, has named Michael D. Becker presi dent and CEO, replacing Daniel Greenleaf, who resigned to pursue other opportunities. Mr. Becker was previously president and CEO of Cytogen, where he led the company’s transformation from a researchdriven biotechnology company into a product focused specialty pharmaceutical company with a growing commercial presence in the U.S. oncology market. He is chairman of BioNJ, a biotechnology industry advocacy group, which was founded in 1994. Mr. Becker attended DePaul University in Chicago. Dr. Martin A. MATTINGLY Trimeris Appoints CEO Trimeris, Morrisville, N.C., a biopharma ceutical company specializing in the develop ment and commercialization of antiviral ther apies, has named Martin A. Mattingly, Pharm.D., as CEO. Dr. Mattingly most recently served as president and CEO of Ambrx Pharmaceuticals. He has also held positions at Agouron Pharmaceuticals, Pfizer, and Eli Lilly. Dr. Mattingly received a doctor of pharma cy degree from the University of Kentucky. Dr. Rainer PABST Peter SEITH Biotest Appoints U.S. Management Team Biotest AG, a German biopharmaceuticals com pany specializing in plas ma proteins, has named Rainer Pabst, Ph.D., as CEO of Biotest Pharma ceuticals, the U.S. divi sion created as part of Biotest’s acquisition of Nabi Pharmaceuticals’ Nabi Biologics busi ness unit. Dr. Pabst was previously managing director of Biotest Pharma GmbH. He has held positions at Bayer and Centeon. Peter Seith, formerly a director of project man agement of Biotest Phar ma GmbH, has been appointed VP of project management of Biotest Pharmaceuticals. In addi tion to heading project management for the Boca Raton, Fla.based organization, Mr. Seith is serving as VP of corporate quality assurance for Biotest Pharma worldwide. Dr. Lesley A. STOLZ Sunesis Appoints Business Development Head Lesley A. Stolz, Ph.D., has been named VP, corporate and business development, of Sune sis Pharmaceuticals, a South San Francisco, Calif.based clinicalstage biopharmaceutical company focused on the discovery, develop ment, and commercialization of small molecule therapeutics for oncology and other lifethreatening diseases. Dr. Stolz was previously senior director, business development of Aerovance, where she led efforts to partner the com pany’s Phase II asset for uncontrolled asthma. She received a B.S. from the University of Virginia and M.S. and Ph.D. degrees from the University of Rochester. Dr. Kleanthis G. XANTHOPOULOS Regulus Therapeutics Names CEO Regulus Therapeutics, Carlsbad, Calif., has appointed Kleanthis G. Xanthopoulos, Ph.D., as president and CEO. Regulus is a joint ven ture between Alnylam Pharmaceuticals and Isis Pharmaceuticals formed to discover, devel op, and commercialize therapeutics using microRNAs, substances believed to regulate the expression of a large number of human genes. Dr. Xanthopoulos, a cofounder and former president and CEO of Anadys Pharmaceuti cals, was most recently a managing director of Enterprise Partners Venture Capital. An Onassis scholar, he received a B.Sc. in biology with honors from Aristotle Universi ty, as well as an M.Sc. in microbiology and a Ph.D. in molecular biology, both from the University of Stockholm. Specialty POOL Kathleen BOZIWICK Dr. Michael E. LUSTY Intranasal Adds to Management Team Intranasal Therapeutics, Montvale, N.J., a specialty pharmaceutical company focused on developing nasally delivered, preservativefree drug products, has made two key additions to its management team. Kathleen Boziwick has been appointed VP, commercial development. Ms. Boziwick pre viously served as director and team leader for Pfizer’s product evaluation group focused on the allergy and respiratory, infectious disease, and vaccine sectors. She received an MBA from Pace University. Michael E. Lusty, Ph.D., has been named VP, pharmaceutical development. Dr. Lusty was most recently VP, aerosol research and 0208issue FINAL 1/18/08 5:37 PM Page 65 66 F e b r u a r y 2008 PharmaVOICE TALENT pool development, of Kos Pharmaceuticals. He received a Ph.D. in physics from the Universi ty of St. Andrews, Scotland. Timothy SAXON Tris Pharma Names Business Development VP Timothy Saxon has been named VP, busi ness development, of Tris Pharma, a Mon mouth Junction, N.J.based company special izing in orally administered drugdelivery technologies. Mr. Saxon most recently served as a business development consultant in the biotechnology field. At Tris, Mr. Saxon spearheads the compa ny’s outlicensing activities and manages opportunities to help the company enhance product life cycles and competitively differen tiate its products. Before this, he worked for Wyeth as assistant VP of global business development. Mr. Saxon received an MBA with distinc tion and top honors from Loughborough Uni versity Business School in England. Dr.Whaijen SOO Shire Human Genetics Business Gains R&D Head Shire’s Human Genet ic Therapies business, based in Cambridge, Mass., has appointed Whaijen Soo, M.D., Ph.D., as senior VP, research and develop ment. Dr. Soo was previ ously senior VP of medi cal research of Biogen Idec. He completed undergraduate studies in chemistry at Nation al Taiwan University. Before that, he spent 18 years at Roche. Dr. Soo received a Ph.D. in biochemistry from the University of California, Berkeley, and an M.D. from the University of California, San Francisco. Dr. Michael SWEENEY Depomed Names Product Development Head Depomed, Menlo Park, Calif., has appoint ed Michael Sweeney, M.D., VP of product development. In addition to overseeing all aspects of product development, Dr. Sweeney is responsible for the commercial medical affairs function of Depomed. Most recently, Dr. Sweeney was VP of med ical affairs of CV Therapeutics, where his lead ership enabled the commercial preparation and successful launch of Ranexa in 2006. Before that, he spent 11 years at Pfizer. Dr. Sweeney received an M.D. from Manchester University, as well as a postgradu ate diploma in pharmacoepidemiology from the University of London. He also holds a postgraduate diploma in pharmaceutical medicine, and is a fellow of the Royal College of Physicians of Edinburgh. Emerging POOL Patrick T. HIGGINS Pharmasset Names Marketing and Sales Manager Pharmasset, Prince ton, N.J., has named Patrick T. Higgins execu tive VP, marketing and sales. Mr. Higgins was recently VP, sales and marketing, virology, at Roche, and since 2006 has served as a consultant to Pharmasset, a clinicalstage pharmaceutical company focused on discovering, developing, and commercializing drugs to treat viral infec tions. Mr. Higgins’ initial responsibilities for Pharmasset’s marketing and sales group include building a team to market clevudine upon its approval for treatment of chronic hepatitis B infection. Mr. Higgins received a B.A. from Villano va University and an MBA from Seton Hall University. CRO POOL Dr.Victor KIRI Parexel Names Pharmacoepidemiology Director Parexel International has appointed Victor Kiri, Ph.D., to director of pharmacoepidemi ology within the company’s clinical research services business. Dr. Kiri’s responsibilities include advising clients in the design and execution of com parative observational studies, offering epidemi ological analysis for com pounds in development, and guiding strategic decisions regarding future areas of research and product develop ment. Most recently, Dr. Kiri managed epidemi ology research of GlaxoSmithKline. He received an M.Sc. degree in operational research from the University of Sussex and a Ph.D. from the University of Bradford. Service POOL Dr. Steven GORDZIEL James “Fred” PRUDEN PharmaDirections Adds to Executive Team Two industry veterans have joined the executive team of PharmaDirections, a drug development management firm based in Cary, N.C. Steven Gordziel, Ph.D., has been appoint ed practice head of phar maceutical development, leading efforts to expand the development of modi fied release and special ized dosage forms. Dr. Gordziel has more than 30 years of experience in the pharmaceu tical industry, most recently as VP, product development, of HollisEden Pharmaceuti cals. He received a B.S. in pharmacy from the Philadelphia College of Pharmacy and a Ph.D. in pharmaceutical sciences from the Universi ty of Connecticut, Storrs. James “Fred” Pruden has been named practice head of manufacturing operations and is expand ing the company’s capaci ty for rapid turnaround of clinical trial materials using PharmaDirections’ proprietary virtual manu facturing systems. Mr. Pruden has more than 35 years of expe rience in pharmaceutical manufacturing and compliance. Most recently, he was VP of manufacturing operations of AAIPharma. 0208issue FINAL 1/18/08 5:37 PM Page 66 TALENT pool MedicalEducation POOL Rich CARACIO Bob DONAHOE Paul KOREN Peter PAYERLI Melissa WARNER CME Restructures Management Team CME LLC, Irvine, Calif., a division of CMPMedica, has reorga nized its management team, naming Melissa Warner senior VP, general manager, and promoting Rich Caracio, Bob Dona hoe, and Peter Payerli as VPs of education initia tives. CME offers a wide range of informational and educational resources for healthcare profession als, including live events and conferences, print supplements, multimedia home study products, and Websites. Mr. Caracio, Mr. Donahoe, and Mr. Payerli were previously executive directors of CME. Ms. Warner was most recently VP and gener al manager of the oncology and radiology divi sions of CMPMedica U.S. CME also has appointed Paul Koren exec utive director of education initiatives. Most recently, Mr. Koren was responsible for gener ating growth for the oncology division of CMPMedica U.S. Beatrix ERIKSEN Marcy HOLETON Kathy MISCHAK Steve SANBORN Beth SCHOLZ CMPMedica U.S. Makes Executive Promotions CMPMedica U.S., the New Yorkbased medical education unit of CMPMedica, Lon don, has announced a number of promotions to the executive management team. Beatrix Eriksen is now VP of research, market ing, and circulation. Ms. Eriksen previously served as group director of research and circulation at CMPMedica U.S. Marcy Holeton was promoted to senior VP and general manager of the primary care and spe cialties businesses. Previ ously, Ms. Holeton was a group VP and general manager. Kathy Mischak is now group publisher for oncology and radiology. In her previous role at CMPMedica U.S., Ms. Mischak oversaw Diagnostic Imaging as the journal’s publisher. Steve Sanborn, who previously held the position of group production manager, is now group director of manufacturing and produc tion. Beth Scholz has been promoted to VP of the oncology and radiology divisions. Previ ously, Ms. Scholz was publisher of CMPMed ica U.S.’s Oncology Publishing Group, which includes Oncology and Oncology News Interna tional. Agency POOL Vincent Dean BOYCE Meghan REILLY Robert SADOWSKI HealthEd Expands Staff HealthEd, Clark, N.J., a developer of patient education programs for pharmaceuti cal and healthcare marketers, has added a number of professionals to its team. Vincent Dean Boyce has been named senior interactive designer responsible for developing initiatives, contexts, frameworks, and inter faces for online and mobile interactive systems. He previously did freelance work for Siemens. He received a BFA in design and technology from Parsons School of Design and a master’s of professional studies in interactive telecommu nications from New York University. Meghan Reilly has joined HealthEd as account coordinator. Ms. Reilly previously worked at Integrated Communications. She received a B.S. in marketing from the Univer sity of Scranton. 0208issue FINAL 1/18/08 5:37 PM Page 67 THE FORUM FOR THE INDUSTRY